Cargando…
Validating α-particle emission from (211)At-labeled antibodies in single cells for cancer radioimmunotherapy using CR-39 plastic nuclear track detectors
Recently, (211)At has received increasing attention as a potential radionuclide for cancer radioimmunotherapy. It is a α-particle emitter, which is extremely effective against malignant cells. We demonstrate a method to verify the efficiency of (211)At-labeled trastuzumab antibodies ((211)At-trastuz...
Autores principales: | Kodaira, Satoshi, Li, Huizi Keiko, Konishi, Teruaki, Kitamura, Hisashi, Kurano, Mieko, Hasegawa, Sumitaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489156/ https://www.ncbi.nlm.nih.gov/pubmed/28658304 http://dx.doi.org/10.1371/journal.pone.0178472 |
Ejemplares similares
-
Evidence of Local Concentration of α-Particles from (211)At-Labeled Antibodies in Liver Metastasis Tissue
por: Kodaira, Satoshi, et al.
Publicado: (2019) -
Contribution to dose in healthy tissue from secondary target fragments in therapeutic proton, He and C beams measured with CR-39 plastic nuclear track detectors
por: Kodaira, Satoshi, et al.
Publicado: (2019) -
Successful radioimmunotherapy of established syngeneic rat colon carcinoma with (211)At-mAb
por: Eriksson, Sophie E, et al.
Publicado: (2013) -
Radioimmunotherapy with an (211)At‐labeled anti–tissue factor antibody protected by sodium ascorbate
por: Takashima, Hiroki, et al.
Publicado: (2021) -
Significant changes in yields of 7-hydroxy-coumarin-3-carboxylic acid produced under FLASH radiotherapy conditions
por: Kusumoto, Tamon, et al.
Publicado: (2020)